Drugs / Antistax
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT02191163 | Apr → Aug 2002 | chronic venous insufficiency | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT02191280 | Apr → Sep 1998 | venous insufficiency | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02191254 | Apr → Oct 2004 | venous insufficiency | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02184234 | Jun → Oct 2001 | venous insufficiency | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Antistax | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02184234 ↗ |
| Route | Oral | “360 mg/Day Per os” NCT02184234 ↗ |